Preconditioning of the tumor microenvironment with oncolytic reovirus converts CD3-bispecific antibody treatment into effective immunotherapy

BACKGROUND: T-cell-engaging CD3-bispecific antibodies (CD3-bsAbs) are promising modalities for cancer immunotherapy. Although this therapy has reached clinical practice for hematological malignancies, the absence of sufficient infiltrating T cells is a major barrier for efficacy in solid tumors. In...

Descripción completa

Detalles Bibliográficos
Autores principales: Groeneveldt, Christianne, Kinderman, Priscilla, van den Wollenberg, Diana J M, van den Oever, Ruben L, Middelburg, Jim, Mustafa, Dana A M, Hoeben, Rob C, van der Burg, Sjoerd H, van Hall, Thorbald, van Montfoort, Nadine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Oncolytic and Local Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577070/
https://www.ncbi.nlm.nih.gov/pubmed/33082167
http://dx.doi.org/10.1136/jitc-2020-001191

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577070/
https://www.ncbi.nlm.nih.gov/pubmed/33082167
http://dx.doi.org/10.1136/jitc-2020-001191

Ejemplares similares